Physician profile
Diana Casanova
NPI 1831267590
$1,325.81
in general payments reported to CMS, 2019-2025
14 companies · $59.56 in 2025
The $59.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $223 · 2021: $251 · 2022: $86.29 · 2023: $101 · 2024: $319 · 2025: $59.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.28 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.70 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $252.74 | 2019-2023 | Mounjaro |
| Pfizer INC. | $117.78 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.73 | 2023-2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $104.48 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $92.61 | 2020-2021 | |
| Glaxosmithkline, LLC. | $88.12 | 2021-2022 | |
| Astellas Pharma US INC | $68.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.61 | 2023 | |
| Allergan, INC. | $24.40 | 2019 | |
| Ardelyx, INC. | $20.81 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $20.19 | 2024 | Voquezna |
| Tactile Systems Technology INC | $19.89 | 2024 | Flexitouch Plus, Entre Plus |
| Eisai INC. | $18.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Casanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.